Skip to main content
Fig. 2 | Journal of Neuroinflammation

Fig. 2

From: Muramyl dipeptide-mediated immunomodulation on monocyte subsets exerts therapeutic effects in a mouse model of Alzheimer’s disease

Fig. 2

Regulation of monocyte subsets and improvement in memory deficits following chronic MDP administration over 3 months (low frequency) in APP mice. a Representative timeline of chronic MDP administration over 3 months (low frequency) in APP and WT mice, APP n = 10 mice per group, and WT n = 5 mice per group. b, c Absolute count of blood inflammatory Ly6Chi monocytes in WT and APP mice and following chronic MDP administration over 3 months (low frequency). Data are expressed as the means ± SEM; $P < or = 0.01 vs. WT-vehicle. c Absolute count of blood Ly6Clow monocytes in WT and APP mice and following chronic MDP administration over 3 months (low frequency). Data are expressed as the means ± SEM; $$P < or = 0.003 vs. WT-MDP, %%P < or = 0.007 vs APP-MDP. d The total number of errors made on day 1 (D1), day 2 (D2), and day 3 (D3) in WT and APP mice in learning performance in position habit acquisition following chronic MDP administration over 3 months (low frequency). Data are expressed as the means ± SEM; ++P < or = 0.002 vs. WT-vehicle D1, **P < or = 0.003 vs. APP-MDP D1, ***P < or = 0.0004 vs APP-MDP D1. Data analyzed using two-way ANOVA for the time points and treatments. e The total number of errors made on day 1 (D1), day 2 (D2), and day 3 (D3) in WT and APP mice in reversal performance in position habit acquisition following chronic MDP administration over 3 months (low frequency). Data are expressed as the means ± SEM; ¥P < or = 0.0266 vs. APP-vehicle D2 and D3, ++++P < or = 0.0001 vs. WT-vehicle D1, ^^^^P < or = 0.0001 vs. WT-MDP D1, %P < or = 0.0092 vs. APP-vehicle D1, ***P < or = 0.0008 vs. APP-MDP D1. Data analyzed using two-way ANOVA for the time points and treatments

Back to article page